Clinical Credence — SGLT2 Inhibitors, Diabetes, and Chronic Kidney Disease
Abstract
This editorial highlights the transformative role of SGLT2 inhibitors in managing type 2 diabetes and chronic kidney disease (CKD). The CREDENCE trial demonstrated that canagliflozin, an SGLT2 inhibitor, significantly reduced the risk of end stage kidney disease, cardiovascular death, and hospitalization for heart failure in patients with diabetic nephropathy. The drug’s renoprotective effects are attributed to mechanisms beyond glucose control, including reduced intraglomerular pressure and systemic inflammation. With a 30% lower relative risk of primary renal outcomes and 20–30% reduction in cardiovascular events, SGLT2 inhibitors represent a dual therapeutic advance. The findings underscore their potential to mitigate the global burden of diabetes related CKD and cardiovascular morbidity.
Keywords:
SGLT2 inhibitors
chronic kidney disease
type 2 diabetes
renoprotection
cardiovascular outcomes
canagliflozin
CREDENCE trial
Article Document
1 / 1
100%